Acipimox , ≥98% , 51037-30-0
Synonym(s):
2-Carboxy-5-methylpyrazine 4-oxide;5-Methylpyrazinecarboxylic acid 4-oxide
CAS NO.：51037-30-0
Empirical Formula: C6H6N2O3
Molecular Weight: 154.12
MDL number: MFCD00865757
EINECS: 256-928-3
| Pack Size | Price | Stock | Quantity |
| 1G | RMB96.00 | In Stock |
|
| 5G | RMB348.00 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 177-180 °C |
| Boiling point: | 539.0±45.0 °C(Predicted) |
| Density | 1.44±0.1 g/cm3(Predicted) |
| storage temp. | Inert atmosphere,2-8°C |
| solubility | Soluble in methanol, water (100 mM), DMSO (100 mM), ethanol (<1 mg/ml at 25° C), and 1 M NH4OH (1 mg/ml). |
| form | Solid |
| pka | 2.80±0.10(Predicted) |
| color | Yellow |
| Merck | 14,111 |
| InChIKey | DJQOOSBJCLSSEY-UHFFFAOYSA-N |
| CAS DataBase Reference | 51037-30-0(CAS DataBase Reference) |
| EPA Substance Registry System | Pyrazinecarboxylic acid, 5-methyl-, 4-oxide (51037-30-0) |
Description and Uses
Acipimox is a nicotinic acid derivate that structurally related to nicotinic acid. Like nicotinic acid, lowers lipids effectively, but unlike nicotinic acid, acipimox is longer acting and therefore much less prone to produce free fatty acid rebounding. It is usually employed in man in the therapy of hypertriglyceridemia. In addition to its lipid lowering activity, it produces a beneficial elevation of the anti-atherogenic high density lipoprotein subfraction, HDL2. Acipimox is recommended as a lipid-lowering agent to treat hyperlipidemia in patients with noninsulin dependent diabetes mellitus.
Acipimox is a long-acting antilipemic agent and used for the treatment of hyperlipoproteinemias, in particular hypertriglyceridemias, and as adjunctive therapy for affecting cholesterol metabolism.
